NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
Hosted on MSN29d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsapproved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for everyone ...
The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a standalone treatment, is "the first and only ...
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback